Theodore F. Logan, MD

1989 Fellowship University of Pittsburgh, Pittsburgh, PA

1984 Residency University of Pittsburgh, Pittsburgh, PA

1981 MD University of Vermont

1974 BA Colby College

My interest is in the use of biologic agents (cytokines, cells, vaccines, etc.) either with or without chemotherapy in the treatment of cancer, especially renal cell cancer.

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.
Voss MH; Bhatt RS; Vogelzang NJ; Fishman M; Alter RS; Rini BI; Beck JT; Joshi M; Hauke R; Atkins MB; Burgess E; Logan TF; Shaffer D; Parikh R; Moazzam N; Zhang X; Glasser C; Sherman ML; Plimack ER; Cancer 2019 Apr 5

NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma.
Tarhini AA; Frankel P; Ruel C; Ernstoff MS; Kuzel TM; Logan TF; Khushalani NI; Tawbi HA; Margolin KA; Awasthi S; Butterfield LH; McDermott D; Chen A; Lara PN; Kirkwood JM; 2018 Oct 10

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma.
Clark JI; Singh J; Ernstoff MS; Lao CD; Flaherty LE; Logan TF; Curti B; Agarwala SS; Taback B; Cranmer L; Lutzky J; Luna TL; Aung S; Lawson DH; 2018 Jul 27

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
Chesney J; Puzanov I; Collichio F; Singh P; Milhem MM; Glaspy J; Hamid O; Ross M; Friedlander P; Garbe C; Logan TF; Hauschild A; Lebbé C; Chen L; Kim JJ; Gansert J; Andtbacka RHI; Kaufman HL; Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Oct 5

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
Chesney J; Puzanov I; Collichio F; Singh P; Milhem MM; Glaspy J; Hamid O; Ross M; Friedlander P; Garbe C; Logan TF; Hauschild A; Lebbé C; Chen L; Kim JJ; Gansert J; Andtbacka RHI; Kaufman HL; 2017 Oct 5

Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM^SM registry.
Curti B; Daniels GA; McDermott DF; Clark JI; Kaufman HL; Logan TF; Singh J; Kaur M; Luna TL; Gregory N; Morse MA; Wong MKK; Dutcher JP; Journal for immunotherapy of cancer 2017 Dec 19

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.
Alva A; Daniels GA; Wong MK; Kaufman HL; Morse MA; McDermott DF; Clark JI; Agarwala SS; Miletello G; Logan TF; Hauke RJ; Curti B; Kirkwood JM; Gonzalez R; Amin A; Fishman M; Agarwal N; Lowder JN; Hua H; Aung S; Dutcher JP; Cancer immunology, immunotherapy : CII 2016 Oct 6

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.
Segal NH; Logan TF; Hodi FS; McDermott D; Melero I; Hamid O; Schmidt H; Robert C; Chiarion-Sileni V; Ascierto PA; Maio M; Urba WJ; Gangadhar TC; Suryawanshi S; Neely J; Jure-Kunkel M; Krishnan S; Kohrt H; Sznol M; Levy R; Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Oct 18

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
Weber JS; Gibney G; Sullivan RJ; Sosman JA; Slingluff CL Jr; Lawrence DP; Logan TF; Schuchter LM; Nair S; Fecher L; Buchbinder EI; Berghorn E; Ruisi M; Kong G; Jiang J; Horak C; Hodi FS; The Lancet. Oncology 2016 Jun 4

Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
Armstrong AJ; Halabi S; Eisen T; Broderick S; Stadler WM; Jones RJ; Garcia JA; Vaishampayan UN; Picus J; Hawkins RE; Hainsworth JD; Kollmannsberger CK; Logan TF; Puzanov I; Pickering LM; Ryan CW; Protheroe A; Lusk CM; Oberg S; George DJ; The Lancet. Oncology 2016 Jan 12

Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.
Amin A; Dudek AZ; Logan TF; Lance RS; Holzbeierlein JM; Knox JJ; Master VA; Pal SK; Miller WH Jr; Karsh LI; Tcherepanova IY; DeBenedette MA; Williams WL; Plessinger DC; Nicolette CA; Figlin RA; Journal for immunotherapy of cancer 2015 Apr 21

Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy.
Bradish JR; Richey JD; Post KM; Meehan K; Sen JD; Malek AJ; Katona TM; Warren S; Logan TF; Fecher LA; Cheng L; Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2014 Nov 7

The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.
McDermott DF; Cheng SC; Signoretti S; Margolin KA; Clark JI; Sosman JA; Dutcher JP; Logan TF; Curti BD; Ernstoff MS; Appleman L; Wong MK; Khushalani NI; Oleksowicz L; Vaishampayan UN; Mier JW; Panka DJ; Bhatt RS; Bailey AS; Leibovich BC; Kwon ED; Kabbinavar FF; Belldegrun AS; Figlin RA; Pantuck AJ; Regan MM; Atkins MB; Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Nov 25

Whole-body PET/CT evaluation of tumor perfusion using generator-based 62Cu-ethylglyoxal bis(thiosemicarbazonato)copper(II): validation by direct comparison to 15O-water in metastatic renal cell carcinoma.
Fletcher JW; Logan TF; Eitel JA; Mathias CJ; Ng Y; Lacy JL; Hutchins GD; Green MA; Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2014 Dec 18

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
Motzer RJ; Rini BI; McDermott DF; Redman BG; Kuzel TM; Harrison MR; Vaishampayan UN; Drabkin HA; George S; Logan TF; Margolin KA; Plimack ER; Lambert AM; Waxman IM; Hammers HJ; Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Dec 1

Foretinib (XL880): c-MET inhibitor with activity in papillary renal cell cancer.
Logan TF; Current oncology reports 2013 Apr

A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer.
Robertson MJ; Kirkwood JM; Logan TF; Koch KM; Kathman S; Kirby LC; Bell WN; Thurmond LM; Weisenbach J; Dar MM; Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Jun 1

Urticaria and angioedema in renal cell cancer patients treated with IL-2.
Logan TF; Strippoli G; Levine MI; Cancer investigation 2007

Interleukins 18 and 21: biology, mechanisms of action, toxicity, and clinical activity.
Logan TF; Robertson MJ; Current oncology reports 2006 Mar

Oncology

American Board of Internal Medicine - Internal Medicine

Renal cell carcinoma; melanoma